Miridesap/Dezamizumab

N/A

Report date: 2022/09/02 17:16:18

Base Information

Drug NameMiridesap/Dezamizumab
Drug Alias NameMiridesap+DezamizumabMiridesap+Anti-SAP mAbMiridesap/Anti-SAP mAbCPHPC+anti-SAP mAbGSK-2315698+GSK-2398852 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionSerum amyloid P-component inhibitors
TargetsSerum amyloid P-component
Therapy Area/IndicationsAmyloidosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes DezamizumabMiridesap
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPentraxin TherapeuticsGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPentraxin TherapeuticsGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsAmyloidosis

Other Information

ATC CodeN/A
Related LinksN/A